Translational Collaboration Hub IBRI positions itself as a first-in-class translational medicine institute uniting academia, industry, and philanthropic partners to accelerate drug discovery. This creates ready-made openings for co-development programs, translational services, and access to lab infrastructure and talent. The IU joint center of excellence and prior collaborations demonstrate receptivity to multi-party partnerships and joint R&D initiatives.

Therapeutic Focus Areas Core focus areas include diabetes and metabolic disease, Alzheimer's disease, and pediatric rare diseases, offering clear opportunities to propose preclinical services, biomarker discovery, model development, and translational assays to pharma partners seeking early-stage assets.

Incubator Model IBRI's incubator-like model to support early-stage companies with investment, talent, and space provides a channel to offer accelerator programs, contract research collaborations, and shared lab facilities to help partner pipelines move faster.

IP Licensing Value With a financing model that sells IP back to industry or spins off discoveries, IBRI presents licensing opportunities for pharma companies seeking early-stage innovations, reduced risk, and near-term revenue potential through exclusive licenses and milestone-driven collaborations.

Collaborative Track Record A track record of collaborations with Allarity, BiomEdit, Insilico Medicine, and Indiana University signals a favorable environment for new partnerships across biotech and pharma, including AI-enabled drug discovery, microbiome applications, and precision medicine.